Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total Vaccinex, Inc. Stockholders’ Equity (Deficit)	Noncontrolling Interests
Balance at Dec. 31, 2020	$ (2,612)	$ 3	$ 250,914	$ (11)	$ (277,481)	$ (26,575)	$ 23,963
Balance, Shares at Dec. 31, 2020		22,388,027		852
Issuance of Common Shares	31,863		31,863			31,863
Issuance of Common Shares, Shares		5,937,900
Stock-based compensation	104		104			104
Shares issued for compensation, Shares		9,979
Exchange of VX3 Units for common shares			2,000			2,000	(2,000)
Exchange of VX3 Units for common shares, Shares		109,900
Net loss	(6,574)				(6,574)	(6,574)
Balance at Mar. 31, 2021	22,781	$ 3	284,881	$ (11)	(284,055)	818	$ 21,963
Balance, Shares at Mar. 31, 2021		28,445,806		852
Balance at Dec. 31, 2021	7,412	$ 3	307,281	$ (11)	(299,861)	7,412
Balance, Shares at Dec. 31, 2021		30,801,962		852
Issuance of Common Shares	13,230	$ 1	13,229			13,230
Issuance of Common Shares, Shares		11,862,941
Stock-based compensation	141		141			141
Net loss	(4,595)				(4,595)	(4,595)
Balance at Mar. 31, 2022	$ 16,188	$ 4	$ 320,651	$ (11)	$ (304,456)	$ 16,188
Balance, Shares at Mar. 31, 2022		42,664,903		852